Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes.
Kevin S Shah, Haolin Xu, Roland A Matsouaka...
https://pubmed.ncbi.nlm.nih.gov/29141781Actively Recruiting
All Genders
ID04990297
Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy
Led by Chinese Academy of Medical Sciences, Fuwai Hospital · Updated on 2022-10-31
2500
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Dilated cardiomyopathy (DCM) is a serious heart condition marked by weakened heart muscle and enlarged heart chambers, leading to risks such as sudden cardiac death or advanced heart failure. Researchers are studying the use of cardiac magnetic resonance (CMR), a detailed imaging method that measures heart mass, volume, and function, to better assess risk and diagnose DCM. This observational study aims to understand how CMR can help in predicting outcomes for people with DCM over a long-term period. Participants will undergo cardiac magnetic resonance imaging to evaluate heart structure and function. The study does not involve experimental treatments but focuses on monitoring patients with DCM using CMR. The study will track outcomes such as all-cause mortality, sudden cardiac death, heart failure worsening, and major adverse cardiac events over a period of 1 to 10 years. During the study, participants will be followed up regularly to assess their health status and heart function using CMR and other clinical evaluations. Researchers will collect data on mortality and cardiac events to analyze risk factors linked to DCM. This long-term observation will help improve understanding of disease progression and potential risk stratification in patients with DCM.
CONDITIONS
Brief Title
Cardiac Magnetic Resonance for Risk Stratification in Dilated Cardiomyopathy
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Reduced left ventricular ejection fraction (LVEF) less than 50%
- Left ventricular end-diastolic volume more than 2 standard deviations above normal based on body size and age
You will not qualify if you...
- Presence of ischemic heart disease confirmed by coronary angiography, perfusion imaging, medical records, or history of acute coronary syndrome or coronary procedures
- Hypertrophic cardiomyopathy, moderate-to-severe valvular disease, or infiltrative diseases like amyloidosis, sarcoidosis, or Fabry disease
- Incessant arrhythmias
- Inability to lie flat
- Pregnancy
- Contraindications to cardiac magnetic resonance such as severe claustrophobia, pacemakers, defibrillators, certain aneurysm clips, intraocular metal, or advanced kidney disease
- Diabetes with end organ damage
- Inability to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 day
Participants undergo cardiac magnetic resonance to assess heart function and structure.
1 visit (in-person)
Long-term Monitoring
Duration - 1 to 10 years
Participants are observed for up to 10 years to track heart-related outcomes and overall health.
Periodic follow-up visits as determined by the study team
Trial Site Locations
Total: 1 location
1
Fuwai Hospital
Beijing, Beijing Municipality, China, 100037
Actively Recruiting
Loading map...
Research Team
M
Minjie Lu, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski, Adriaan A Voors, Stefan D Anker...
https://pubmed.ncbi.nlm.nih.gov/27207191Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study.
Eric C Stecker, Catherine Vickers, Justin Waltz...
https://pubmed.ncbi.nlm.nih.gov/16545646Risk prediction in patients with heart failure: a systematic review and analysis.
Kazem Rahimi, Derrick Bennett, Nathalie Conrad...
https://pubmed.ncbi.nlm.nih.gov/25194291Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets.
Arata Fukushima, Kenneth Milner, Abhishek Gupta...
https://pubmed.ncbi.nlm.nih.gov/26166604Myocardial Strain in the Assessment of Patients With Heart Failure: A Review.
Thomas H Marwick, Sanjiv J Shah, James D Thomas
https://pubmed.ncbi.nlm.nih.gov/30810702Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations.
Vanessa M Ferreira, Jeanette Schulz-Menger, Godtfred Holmvang...
https://pubmed.ncbi.nlm.nih.gov/30545455The evaluation of non-ischemic dilated cardiomyopathy with T1 mapping and ECV methods using 3T cardiac MRI.
Cemile Ayşe Görmeli, Zeynep Maraş Özdemir, Ayşegül Sağır Kahraman...
https://pubmed.ncbi.nlm.nih.gov/27785679Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy.
Andrea Barison, Alberico Del Torto, Sara Chiappino...
https://pubmed.ncbi.nlm.nih.gov/26090916Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy.
Keisuke Inui, Kuniya Asai, Masaki Tachi...
https://pubmed.ncbi.nlm.nih.gov/29560528